Literature DB >> 10517980

Studies using specific biomarkers for human exposure assessment to exogenous and endogenous chemical agents.

P B Farmer1.   

Abstract

The extent of formation of carcinogen adducts with DNA and protein may be used to assess the biologically effective dose of these carcinogens in the tissue under study. In normal human tissues, such carcinogen adducts arise in part from exposures to exogenous genotoxic compounds, although it has been shown that endogenously formed carcinogens also make a significant contribution to the observed DNA and protein damage. Although, highly sensitive analytical methods, such as immunoassay, 32P-postlabelling and mass spectrometry have been developed and successfully applied to measure carcinogen adducts, further methodological advances are making these methods more amenable to molecular epidemiological studies. Thus, the use of immunoslot blot assays allows a higher sample throughput for adduct quantification. Liquid chromatographic separations of adducts, either for their radiochemical detection following 32P-postlabelling or for their determination by mass spectrometry, improves the specificity and applicability of these techniques. In this review, the sensitivities and specificities of the analytical methods used for adduct detection are compared and the limitations of these methods described.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10517980     DOI: 10.1016/s1383-5742(99)00033-2

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  2 in total

Review 1.  Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools.

Authors:  Anthony E Pegg
Journal:  Chem Res Toxicol       Date:  2011-04-28       Impact factor: 3.739

Review 2.  Proteomic approaches to characterize protein modifications: new tools to study the effects of environmental exposures.

Authors:  Daniel C Liebler
Journal:  Environ Health Perspect       Date:  2002-02       Impact factor: 9.031

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.